Abstract 1497P
Background
Resuscitation decisions in cancer patients continue to challenge Healthcare Professionals (HCPs) and often do not take place until clinical deterioration, risking futile Cardiopulmonary Resuscitation (CPR) attempts. This research investigated outcomes of In-Hospital Cardiopulmonary Arrest (IHCA) in advanced cancer within an NHS Trust in the UK, alongside viewpoints of HCPs.
Methods
This mixed-methods study comprised two components. Retrospective data analysis examined IHCA outcomes in patients with advanced cancer in Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH) between 2012-2022. Main outcomes included rate of Return of Spontaneous Circulation (ROSC) and survival to discharge. Other outcomes were median overall and post-discharge survival. A survey was distributed to senior HCPs in Acute Medicine (AM), Emergency Medicine (EM) and Oncology, to establish perceptions of CPR success in advanced cancer, and gather current opinion on issues surrounding resuscitation in this context.
Results
Among 83 patients, rate of ROSC was 33.7% and 9.6% survived to discharge. Among survivors, median overall survival was 2 days, and post-discharge survival 391 days. 92 HCPs responded to the survey. The mean likelihood of a patient with advanced cancer achieving ROSC was estimated at 13.4%. Oncologists were ranked the most appropriate HCP to discuss resuscitation, and outpatient clinic appointments the most suitable place. From analysis of text comments, important themes were (1) Place, person and timing, (2) Individualised decision-making, and (3) Improving patient understanding.
Conclusions
Survival following CPR is poor in advanced cancer, and fewer than 10% patients in this study gained any meaningful survival benefit. A collective approach is needed from HCPs to integrate personalised discussions about future care and resuscitation into routine cancer management. These should begin early rather than at a time of crisis, with someone the patient trusts. Blanket decisions are not suitable for any patient and cannot supersede clinical judgement alongside assessment of patient priorities and values.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Newcastle Hospitals Charity.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10